Jin Zhang M.D., Ph.D

Both foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.

Jin Zhang provides an overview of China's major bispecific antibody developers.

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.